Mechanism of Action of Meglitinides

Introduction

Meglitinides, also known as glinides, are short-acting insulin secretagogues used in the treatment of type 2 diabetes mellitus. They function similarly to sulfonylureas but have a more rapid onset and shorter duration of action, making them ideal for postprandial glucose control.

Common meglitinides include:

• Repaglinide
• Nateglinide

These drugs are especially useful for meal-time glucose spikes and are suitable for patients with erratic eating patterns. They are tested in USMLE, NCLEX, GPAT, and NIPER pharmacology sections.

---

Stepwise Mechanism of Action of Meglitinides

1. Binding to SUR1 receptor
   Meglitinides bind to the sulfonylurea receptor-1 (SUR1) on pancreatic beta cells, which is part of the K⁺-ATP channel complex.
2. Closure of K⁺-ATP channels
   This binding closes the potassium channels, preventing potassium efflux.
3. Membrane depolarization
   Accumulated intracellular potassium causes depolarization of the beta-cell membrane.
4. Opening of voltage-gated calcium channels
   Depolarization triggers calcium influx via voltage-dependent calcium channels.
5. Stimulation of insulin secretion
   The rise in intracellular calcium promotes exocytosis of insulin granules, increasing plasma insulin levels.
6. Glucose-dependent effect
   Compared to sulfonylureas, meglitinides have a lower risk of prolonged hypoglycemia because they are more glucose-dependent in action.

---

Pharmacokinetic Parameters of Meglitinides

Drug	Onset	Peak Effect	Duration	Metabolism	Excretion
Repaglinide	~30 minutes	1 hour	4–6 hours	Hepatic (CYP3A4)	Biliary
Nateglinide	~20 minutes	0.5–1 hour	~4 hours	Hepatic (CYP2C9, CYP3A4)	Renal/Biliary

---

Clinical Uses of Meglitinides

• Type 2 diabetes mellitus (especially for postprandial hyperglycemia)
• Alternative to sulfonylureas in patients with irregular meal schedules
• Often used in combination with metformin

---

Adverse Effects of Meglitinides

• Hypoglycemia (less common than sulfonylureas)
• Weight gain
• GI disturbances – bloating, nausea
• Upper respiratory tract infections (rare)
• Headache and dizziness

---

Comparative Analysis: Meglitinides vs Sulfonylureas

Feature	Meglitinides	Sulfonylureas
Onset of action	Rapid	Moderate
Duration	Short (~4 hours)	Long (up to 24 hours)
Receptor target	SUR1 (different site)	SUR1
Hypoglycemia risk	Lower	Higher
Dose timing	With meals	Once or twice daily
Use in irregular meals	Suitable	Not preferred

---

Practice MCQs

Q1. Meglitinides exert their effect primarily by:
a. Enhancing insulin sensitivity
b. Inhibiting glucose absorption
c. Stimulating insulin secretion ✅
d. Blocking DPP-4

Q2. Which receptor do meglitinides bind to?
a. GLP-1 receptor
b. Sodium-glucose co-transporter
c. Sulfonylurea receptor-1 (SUR1) ✅
d. Insulin receptor

Q3. Which potassium channel is inhibited by meglitinides?
a. ROMK
b. K-ATP channel ✅
c. Na⁺/K⁺ pump
d. Calcium channel

Q4. Why are meglitinides preferred in patients with irregular meal times?
a. They are insulin-sparing
b. They are long-acting
c. They work rapidly and briefly ✅
d. They increase satiety

Q5. What is the main adverse effect of meglitinides?
a. Diarrhea
b. Hypoglycemia ✅
c. Bradycardia
d. Constipation

Q6. Repaglinide differs from sulfonylureas in that it:
a. Acts slower
b. Inhibits glucose absorption
c. Has shorter duration of action ✅
d. Does not stimulate insulin

Q7. What is the preferred route of meglitinide excretion?
a. Renal
b. Biliary ✅
c. Pulmonary
d. Pancreatic

Q8. Which enzyme metabolizes nateglinide?
a. CYP1A2
b. CYP2C9 ✅
c. CYP2D6
d. CYP2E1

Q9. Meglitinides are structurally similar to:
a. Thiazolidinediones
b. DPP-4 inhibitors
c. Sulfonylureas ✅
d. Alpha-glucosidase inhibitors

Q10. Which of the following is an advantage of meglitinides?
a. Longer glucose control
b. Glucose-dependent insulin secretion ✅
c. Hypoglycemia in fasting
d. Increased insulin resistance

---

FAQs

Q1: Are meglitinides insulin sensitizers?
No. They are insulin secretagogues, acting on beta cells.

Q2: Can meglitinides be used in type 1 diabetes?
No. They require functional beta cells and are ineffective in type 1 diabetes.

Q3: What is the timing of meglitinide administration?
They are taken 15–30 minutes before meals to target postprandial glucose spikes.

Q4: Are meglitinides safer than sulfonylureas?
They have a lower risk of prolonged hypoglycemia, especially in elderly or renal impairment.

---

References

• KD Tripathi – Essentials of Medical Pharmacology
• Goodman & Gilman – The Pharmacological Basis of Therapeutics
• Review of Pharmacology – Sparsh Gupta
• ADA Guidelines on Diabetes Management
• NCBI: https://www.ncbi.nlm.nih.gov/books/NBK544311/